- BEAT continues impressive march forward in developing a suite of products designed to detect heart attacks anytime, anywhere
- Inventions protected by patent enable proprietary 3D vector ECG technology to be built into a smartwatch
- Projections for global smartwatch and wearables medical-device markets show consistent upward growth
In a world where an estimated 202.6 million people use smartwatches (https://ibn.fm/zb66P), the ability to harness the power of smartwatches to help people live healthier lives can make a profound difference. That’s exactly what HeartBeam (NASDAQ: BEAT), a cardiac technology company with a track record for innovation and cutting-edge technology, hopes to do with its newest patent.
The company announced on November 16, 2022, that it was granted a patent for its 12-lead electrocardiogram (“ECG”) smartwatch-based monitor design to identify heart attacks and…
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork.